other material
confidence high
sentiment positive
materiality 0.65
Arvinas/Pfizer report updated Phase 1b combo data of vepdegestrant + palbociclib; consistent with prior
ARVINAS, INC.
- Clinical benefit rate 63% across all doses; at RP3D 200 mg, CBR 67%; ORR 42% overall, 53% at 200 mg.
- Median progression-free survival 11.2 months across doses; at 200 mg, mPFS 13.9 months (95% CI: 8.1-NR).
- Median duration of response 14.6 months in 13 responders; safety consistent with prior, Grade 3/4 neutropenia 91%.
- ctDNA showed marked reduction in tumor fraction (-98.9%) after one cycle regardless of ESR1 mutation status.